Hospital for Special Surgery, New York
This clinical study is a non-randomized, consecutive, single-center, retrospective-prospective investigation of patients who received NMP bioimplant (Induce Biologics, Tampa, FL) in lumbar spinal fusion procedures. The purpose of this study is to assess the radiographic, clinical, and safety outcomes of Natural Matrix Protein (NMP) as a graft alternative in lumbar fusion procedures. Utilizing the Hospital for Special Surgery's EPIC database under Institutional Review Board approval, all patients with symptomatic lumbar degenerative disc disease who failed conservative management at up to four vertebral levels between L1-S1 between February 2024 and December 2025 will be reviewed. The inclusion criteria for the study will be adult patients (≥ 18 years old) who underwent lumbar fusion with an NMP graft and interbody cage. The exclusion criteria will include previous lumbar fusion attempts, active malignancy, concurrently under chemotherapy, active infection at time of surgery, mentally compromised, and trauma to the operated region. It is expected approximately 100 patients will fit the inclusion/exclusion criteria. The objective of the study is to evaluate the clinical outcomes of the subjects treated with NMP
Retrospective Data Collection: Patient data was collected into a data sheet to collect specific elements that relate to safety and efficacy of the procedure utilizing this specific device system. The data elements of interest are: Patient Summary data (where appropriate: average, sd, range): Subject demographics Distribution of primary diagnoses Surgical Information: Length of constructs with note of non-contiguous constructs Levels treated Patient Assessments and Questionnaires prior to surgery Type and brand of interbody implant(s) used (if applicable) Induce and other bone graft materi…
Inclusion Criteria: * Patients experiencing symptomatic lumbar degenerative disc disease who failed conservative management at up to four vertebral levels between L1-S1 between February 2024 and December 2024. * Adult patients (≥ 18 years old) who underwent lumbar fusion with an NMP graft and interbody cage Exclusion Criteria: * Previous lumbar fusion attempts at the level of surgery (adjacent lumbar levels are acceptable) * Active Malignancy * Concurrently under chemotherapy * Active infection at time of surgery * Mentally compromised * Trauma to the operated region
surgical procedure
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.